Evidence map›Paper›PMID 25916431›Full record

ArticleJournal of endocrinological investigation2015

Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.

S Cannavo, F Bogazzi, A Colao, L De Marinis, P Maffei, R Gomez, E Graziano, M Monterubbianesi, S Grottoli, “Italian Acrostudy Group”

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Pegvisomant in acromegaly: an update.Journal of endocrinological investigation · 2017
    Review
  7. Daily life reflections of acromegaly guidelines.Journal of endocrinological investigation · 2017
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

S CannavoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
F BogazziDepartment of Endocrinology and Metabolic Diseases, Ospedale Cisanello, Pisa, Italy.
A ColaoEndocrinological Clinic, Departmeno of Endocrinology and Molecular and Clinic Oncology, Policlinico Universitario Federico II, Naples, Italy.
L De MarinisInstitute of Endocrinology, Cattolica del Sacro Cuore University, Policlinico A. Gemelli, Rome, Italy.
P MaffeiIII Medical Clinic, Department of Medicine, Azienda Ospedaliera di Padova, Padua, Italy.
R GomezPfizer Europe Medical Affairs, Endocrinology, Puurs, Belgium.
E GrazianoPfizer Italia, Medical Department Endocrinology, Rome, Italy.
M MonterubbianesiPfizer Italia, Medical Department Endocrinology, Rome, Italy.
S GrottoliDepartment of Medicine, Division of Endocrinology, Diabetology and Metabolism, Città della, Salute e della Scienza di Torino, University of Torino, Turin, Italy. silvia.grottoli@unito.it.
“Italian Acrostudy Group”
Pfizer (United States) · USUniversità Cattolica del Sacro Cuore · ITUniversity of Messina · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITOspedale Cisanello · ITPfizer (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data collected during a 7-year period.

methodsA total of 204 acromegaly patients treated by seven centers enrolling 16-49 patients each (group A) and 137 subjects by 18 centers following 3-14 cases ( group B).

resultsPatients of group A and B were treated for 4.4 ± 2.7 and 4.2 ± 2.2 years, respectively. IGF-1 ULN normalized in 64.4 % (n = 56) and 54.4 % (n = 31) in group A and B, respectively, after 1-year treatment, and in 57.3 % (n = 106) and 72.5 % (n = 87) at last visit. Starting doses were significantly higher in group A. They were progressively increased during treatment in both groups, but were higher in uncontrolled patients than in controlled ones only in group A. Reported adverse events were more frequent, and the prevalence of patients with adverse events was higher in group B.

conclusionsOn the basis of this original study approach, we could speculate that in the centers in which more patients are treated with pegvisomant, less adverse events are reported, but the long-term effectiveness is lower than in centers with less cases, perhaps because of an inadequate patient's selection.

Indexed as

AcromegalyAdultFemaleHormone AntagonistsHuman Growth HormoneHumansMaleMiddle AgedReceptors, SomatotropinTreatment OutcomeHormone AntagonistsHuman Growth HormonepegvisomantReceptors, SomatotropinAcromegalyGHHub and spokeIGF-1Pegvisomant

Identifiers

PMID25916431
OpenAlexW2079848379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.